Recent legal changes, introduced by EA PO, allows to include national patents in the EA pharmaceutical registry (active from March 2021); however, not every member country is yet willing to submit actual information on its patents. Therefore, national registries of pharmaceutical patents are still necessary.
Russian registry is still in its prototype stage and it is expected that legal framework shall be finished soon. Yury Zubov, head of RU PTO, recently stressed a necessity of parallel registry, deriving from experience, already available in EAPO. The head of the latter, Grigory Ivliev, confirmed the EA legal base is ready and theoretically every claimant may add a national patent to EA registry. But not all national PTOs are willing to provide restricted information on the patents, so the registry is doomed to be incomplete till then.
The past year has been a period of active and productive work for our team.…
The Eurasian Patent Organization (EAPO) has approved a sweeping increase in official fees for Eurasian…
According to the latest WIPO World Intellectual Property Indicators 2025 report, global patenting activity reached…
The Presidium of the Russian Court for Intellectual Property Rights has upheld the decision of…
We are delighted to announce that our Managing Partner, Maria Nilova, will represent Patentica at…
The Intellectual Property Court of the Russian Federation has issued a definitive ruling in case…